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Abstract
Membrane vesicles (MVs) are the nano-sized structures membrane lipid formed from budding 
off of the outermost membrane of a cell. MVs are known to package a variety of cargo, including small 
molecules, peptides, proteins and genetic material. Based on their assorted cargo, MVs are known to 
transport DNA, RNA, and Proteins across the extracellular space. The unique characteristics could be 
utilized for therapeutic applications.
In this study, Escherichia coli (E. coli) BW25113 strain will be engineered to mass produce 
DNA containing MVs by knocking out the NlpI gene and transforming with Red Fluorescent 
Protein(mCherry). Also, INV (gene for invasion)/LLO (gene synthesizing listeriolysin O) plasmid will 
be transformed into the E. coli strains for active transport of the MVs into the target mammalian cell. 
The characteristic of these vesicles will be analyzed using Qubit 3 fluorometer system to measure the 
concentration of the MVs produced and DNAs in the vesicle. We will also analyze the transfect ability
of the MVs produced to the mammalian cell lines such as Hela, the human cervical cancer cell, and 
HEK293, the human embryonic kidney cell, which are good models for transfection. The toxicity and 
the immunogenicity of invasive vesicles will be characterized using MTT assay and Enzyme-Linked 
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1.1 Transfection of mammalian cell
As a modern biological understanding and technology improve, the needs for patient-specific 
treatment increases.[1] The genetic manipulation is a key technique for both enriching the biological 
knowledge and developing individualized gene therapy.[2] The transfection is the core technology used 
in the laboratory to reveal the function of the specific gene or protein of interest.[3, 4] Thus varieties of 
transfection methods have been developed.[5, 6] The methods can be categorized into three different 
departments; a primarily developed biological method, a chemical method that is widely used in 
laboratory and easy to use, and Physical method.
In biological transfection, a viral vector was first developed to transduce the DNA of interest 
into a human cell. By utilizing the viral vector, the gene of interest can be inserted into the expression 
vector and virus can transfer the plasmid into the target cell.[7] The virus can be applied to in vivo with 
high expression rate once transfected due to viral expression vector has viral promotor which is 
overexpressed in target mammalian cell. [8] Despite its advantages, the viral vector is difficult to mass 
produce since the virus requires a host in order to grow. Likewise, the generation and titration of the 
vector are cumbersome. The viral vector can possibly generate unexpected mutation or induce immune 
response due to its viral structure.[9-12]
Chemical method is generally used to transfect the mammalian cells. Chemicals such as 
calcium phosphate, cationic polymers, and cationic lipid from liposomes bind to the backbone of the 
DNA which has a negative charge due to the phosphate group and delivers to the target cell. Although 
it is only applicable in vitro, chemical transfecting agents have high transfection efficiency and 
reproducibility and is easy to use, therefore has been commercialized and widely used in the 
laboratory.[13-16]
The physical method includes electroporation, laserfection, optoinjection, and direct injection 
using gene gun. Each method is applicable in specific conditions that electroporation results in high cell 
death so that it is well used for bacterial cells but seldom used for mammalian cells, or that laserfection 
and optoinjection yields are high, however, only applicable in vitro and requires sophisticated 
instruments.[17-20] The gene gun is simple and rapidly transfect; just aim and shot, without any treatment 
or duration, with limited application in vivo; muscle and tumor region, however, it is quite expensive 
for low transfection efficiency.[21] is summarized in Table 1.1.1 
Reviewing the advantages and limitations of current transfection methods (Table 1.1.1) 
revealed that there is no sufficient method that can be both applicable in vivo and in vitro with high 
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transfection efficiency and less immunogenicity and cytotoxicity. Therefore, I suggest bacterial 
membrane vesicle as a DNA vector. Recently, bacterial membrane vesicles are gaining much importance 
because their role in pathogenesis can actually be beneficial.[22]
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Table 1.1.1 Transfection Current Method Summary[23]





Compatible for in vivo delivery
Stable expression
Generation and titration of virus particles
Difficult to produce in large quantity






High efficiency and reproducibility
Easy
Commercialized
Low in vivo efficiency
Physical: Electroporation Voltage pulse Delivery into any cells
High cell death
Difficult to apply in vivo
Physical: magnetic nanoparticle Magnetic nanoparticles Increased transfection Requires adherent cell
Physical: Gene gun Heavy metal particles




Physical: Laserfection/ Optoinjection Laser light High transfection efficiency Expensive laser microscope system
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1.2 Bacterial Membrane Vesicles
Membrane vesicles (MVs) are the nano-sized structures secreted by bacteria[24] and are 
produced to deliver the intracellular contents to the extracellular space. Eukaryote cells and Bacterial 
cells produce different kinds of membrane vesicles, for example, Gram-negative bacteria produce Outer 
membrane vesicles. MVs are known to package a variety of cargo, including small molecules, peptides, 
proteins and genetic material.[25] Based on their assorted cargo, MVs have been implicated in many 
biological processes ranging from cell-cell communication to gene transfer and the delivery of virulence 
factors, all of which depend on the bacterium producing the MVs. Outer membrane vesicles from Gram-
negative bacteria can be involved in cell to cell signaling and communication and be mediators of 
immune regulation and pathogenesis. By virtue of their small size, their demonstrated ability to 
transport proteins, and their capacity to associate with mammalian cells in a receptor-dependent 
manner,[26] MVs present themselves as potential biotechnological tools for use in medicine and research. 
Moreover, recent developments in molecular biology techniques have led to engineered MVs and their 
application in some very exciting and unique applications where traditional nanoparticles are proving 
too difficult to employ.[27]
1.2.1 Outer Membrane Vesicle as a Vehicle to Deliver the Macromolecules in high 
concentration
On membrane vesicle formation, the membrane proteins and lipids selectively concentrate 
certain macromolecules on the site of the vesicle formation so that vesicle achieves a higher 
concentration of certain macromolecule than the concentration in the bacterial cytoplasm.[25, 28] The 
membrane vesicle provides protection from protease as well as DNase so that the protein or DNA cargo 
inside the vesicle is safely delivered to the target cell.[25]
1.2.2 MVs Deliver cargo across the Kingdom
Membrane vesicles deliver macromolecules not only between Bacteria[29] or Eukaryotic[30], but 
also between Bacteria and eukaryote.[31] By virtue of its small size, an ability to transport proteins and 
largely sized genes, and capacity to associate with mammalian cells in a receptor-dependent manner,
MV presents itself as a potential biotechnological tool to be used in the medical development and 
biological research.[32] Moreover, recent developments in molecular biology techniques have enabled 
massive production of MVs from Escherichia coli[33] and have led to engineered MVs and their 
application in emerging medical area of biosimilar and drug delivery system[31] where traditional 
methods are proving to be too difficult to employ due to several obstacles in mass production as well 
as in application to varying conditions and needs.[10-12, 14-21]
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1.3 Engineering Bacteria to Produce Membrane Vesicles for gene delivery
The wild-type strain of E. coli BW25113 does not produce enough amount of vesicles. In order 
to utilize the model bacteria, Escherichia coli, the type strain should be genetically modified to increase 
the production of vesicles and the transfection efficiency. The gene that I want to transfect also should 
be incorporated into the vesicle producer. There are several genes that are known to increase invasion 
of the bacteria and production of the vesicle. Invasin from Yersinia pseudotuberculosis and Listeriolysin 
from Listeria monocytogenes can enhance the bacterial invasion compared to non-recombinants[34-36]. 
The scheme of genetic engineering of MV producing E. coli BW25113 strain is shown (Figure 1.3.1)
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Figure 1.3.1 Scheme of E. coli Genetic Modification to produce invasive MVs
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1.3.1 Invasin and Listeriolysin: Promotes Invasion into the Mammalian cell
Invasin is a virulence factor from Yersinia pseudotuberculosis that increases invasion rate 
when expressed in E. coli compared to non-recombinants. Invasin regulates adhesion and entry into the 
target mammalian cell through β-integrin.[35, 36]
Listeriolysin O(LLO) is a virulence factor from Listeria monocytogenes that allows bacteria 
to escape from vacuoles formed when bacteria invade into the target mammalian cell and to enter into 
the cytosol of the target cell. LLO can lyse the phagocytic endosome which will also increase the 
transfection efficiency.[34, 37]
Incorporating both INV plasmid which codes the invasion[35] and LLO plasmid which codes
listeriolysin O, the recombinant bacteria produces invasin and listeriolysin O which localizes to the 
outer membranes of the bacteria[34]. The recombinant bacteria produce vesicles with the increased
invasion to the target mammalian cell.
1.3.2 NlpI knock-out Overproduces Membrane Vesicle
E. coli itself cannot produce sufficient amount of vesicle. In order to mass produce the vesicles, 
the process of the biogenesis of the vesicle should be considered. Vesicles form as the outer membrane 
of the bacteria bud off.[22] The budding of the outer membrane occurs in the area that lacks the outer 
membrane-peptidoglican linking proteins. Thus, by disrupting the peptidoglycan layer, the vesiculation 
can be enhanced. In order to increase the vesicle production, candidate genes for vesiculation such as 
NlpI deletion have been considered. NlpI is a negative regulator of the peptidoglycan(PG) hydrolases. 
The deletion of nlpI results in instability of outer membrane due to PG dynamics which increases the 
vesiculation rate.[33, 38, 39] Therefore, nlpI deletion mutants which are known to show hyper-vesiculation 
was used in this study.
In this study, the potential of MV to be developed as a transfecting agent are demonstrated 
with Escherichia coli which are engineered to overproduce MVs by deletion of the nlpI gene. The 
engineered E. coli BW25113 NlpI knock-out strains yield about 100-fold higher production of MVs 
than E. coli BW25113 wild-type. The mass produced MVs are loaded with the fluorescence gene such 
as mCherry having mammalian promotor so that when the MVs, loaded with the dsDNA plasmid, are 
treated to the mammalian cell, the mammalian cell will be transfected with the fluorescence gene. 
Having fluorescence as an indicator of the successful transfection, the transfection using MVs was 
analyzed. The cytotoxicity and immunogenicity of the MVs to the transfected mammalian cell lines 
have been measured using the MTT assay, live-dead staining, and ELISA. 
Throughout the study, we have demonstrated the potential development of the MVs as an 
efficient transfecting agent. Using MV as a transfecting agent instead of chemical transfection would 
pose a variety of advantages from low toxicity to in vivo applications as well as targeted transfection by 
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engineering MVs to have specific antigen to bind to a specific target cell. Since the genetic therapeutics 
is emerging strategy in personalized medication, such aspects will be beneficial. 
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Chapter 2 Experimental Method & Materials
2.1 Bacterial strain and growth conditions
Escherichia coli BW25113 was obtained from Keio collections. The vesicle overproducing 
strains were obtained by deletion of the nlpI gene that was done by Dr. Monnappa and Mr.Son. E. coli 
BW25113 ∆nlpI, E. coli BW25113 ∆nlpI INV/LLO, E. coli BW25113 ∆nlpI pCMV mCherry, E. coli
BW25113 ∆nlpI pCMV mCherry INV/LLO were all obtained by transformation of each plasmid. 
Strains were maintained in 25% glycerol stock at -80°C. Strains of need were streaked on Luria-Bertani 
broth agar plates (BD DifcoTM, USA) with proper antibiotics for each plasmid transformed into the 
bacteria and grown overnight at 37°C. The bacteria with pCMV mCherry was grown with 50μg/ml of 
kanamycin, and the one with INV/LLO gene plasmid was grown with 35μg/ml of chloramphenicol, and 
the bacteria with Lux gene plasmid was grown with 100μg/ml of ampicillin. From the agar plates, a
single colony was taken by the disposable loop and inoculated into LB broth and grown at 37°C 
overnight with agitation (250rpm) in shaking incubation.
2.2 Culture of human cervical cancer cell line (Hela cells)
Human Cervical cancer cells (Hela cells) were stocked in 5% DMSO with the complete media
in 2ml cryo-tube and stored in liquid nitrogen (-200°C). Upon demand, one stock, total of 1ml, were 
taken out to be plated on the T25 flask using whole stock with 5ml of MEM (1X) [+] Earle’s Salts, [+] 
L-Glutamine media (Gibco®, USA) with 10% FBS and antibiotic Normocin (InvivoGen, USA) 
100μg/ml. After overnight growth in the 5% CO2 incubator at 37°C, the media was changed to remove 
the remaining DMSO. Removal and handling with the mammalian cell media are done with a
serological pipet(SPL LIFE SCIENCES, Republic of Korea). When the Hela cells become confluent, 
media were removed and cells were washed with sterile DPBS and trypsinized using Trypsin-EDTA(TE)
for 5 minutes at 37°C. The detached cells were washed with 10ml of complete media (MEM + 10% 
FBS + 100μg/ml Normocin) and collected in 50ml tube, then centrifuged for 5 minute, 
1500rpm(5600rcf). The supernatants were discarded to remove TE and 10ml of fresh complete media 
were added to the cell pellets and resuspended. the proper volume of cells, depending on cell 
concentration, ranging from 0.5ml to 2ml were added to 15ml of complete media in the T75 flask
(75cm2, Filter Cap, SPL LIFE SCIENCES, Republic of Korea). After culturing cells until they are 
confluent, the same trypsinization steps were processed. The confluency of the cell was observed on 
OLYMPUS CKX31(OLYMPUS Corporation, Japan). Using hemocytometer (iNCYTO, DHC-N01-5), 
cells were counted and diluted appropriately to be plated in an appropriate culture dish for the 
experiment.
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2.3 Culture of human embryonic kidney cell line (HEK293 cells)
Embryonic kidney cells (HEK293 cells) were stocked in 5% DMSO with the complete media 
and stored in liquid nitrogen (-200°C). Upon demand, one stock, total of 1ml, were taken out to be 
plated on the T25 flask using whole stock with 5ml of DMEM-F12 media with sodium carboxide 
(Gibco®, USA), 10% FBS and antibiotic Normocin (InvivoGen, USA) 100μg/ml. After overnight 
growth in the 5% CO2 incubator at 37°C, the media was changed to remove the remaining DMSO. 
When the HEK293 cells become confluent, media were removed and cells were washed with sterile 
DPBS and trypsinized using Trypsin-EDTA(TE) for 5 minutes at 37°C. The detached cells were washed 
with 10ml of complete media (DMEM + 10% FBS + 100μg/ml Normocin) and collected in 50ml tube, 
then centrifuged for 5 minute, 1500rpm(5600rcf). The supernatants were discarded to remove TE and 
10ml of fresh complete media were added to the cell pellets and resuspended. the proper volume of 
cells, depending on cell concentration, ranging from 0.5ml to 2ml were added to 15ml of complete 
media in the T75 flask. After culturing cells until they are confluent, the same trypsinization steps were 
processed. Using hemocytometer, cells were counted and diluted appropriately to be plated in an 
appropriate culture dish for the experiment.
2.4 Transformation of the bacterial strain 
The cell of interest was streaked onto the LB agar(1.6~1.7%) plate with proper antibiotics and 
incubated at 37°C for overnight. A single colony was taken for inoculation in 5ml of LB broth in a 15ml
tube(Falcon) and incubated at 37°C shaking incubator. The inoculants were taken to be diluted 100 folds 
according to OD600 1.0 in 5ml LB in a 15ml tube. The diluents were incubated until the OD600 0.3 for 3 
to 4 hours at 37°C shaking incubator. 1ml of inoculum were centrifuged in the 1.5ml tube(SPL LIFE 
SCIENCES, Republic of Korea) for 1 minute at max speed. Supernatants were removed and cell pellets
were washed with ice-cold(4°C) 10% glycerol 500μl, 250μl, 100μl, each time centrifuging for 1min, 
max speed, at 4°C. Washed cell pellets were resuspended and mixed with 2ng of the plasmid. 20μl of 
the mixture was placed in ice-cold electrophoresis cuvette (BIO-RAD, Gene Pulser® Cuvette) and 
inserted into the electroporator(Eppendorf, Electroporator 2510). After applying 1800V current, the
mixture was resuspended in 200μl of LB media without antibiotics and incubated at 37°C for 30 minutes 
to 1 hour. The samples were plated on proper LB agar plate and incubated at 37°C overnight. Some of 
the colony (10 to 20 colony) are selected and patched on new plate, them the plasmid from the colony 
were purified using plasmid & DNA purification kit (COSMO GENETECH, Republic of Korea) and 
the size of the plasmid was determined using electroporation with 1% agar gel (Molecular Biology
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Grade, PhileKorea TECH INC, Republic of Korea) and checked with Molecular Imager® Gel DocTM
XR+(BIO-RAD, USA) for confirmation. Recombinant strains were inoculated in 5ml LB overnight and 
stored in 25% glycerol at -80°C.
2.5 Membrane vesicle isolation
Vesicle producing strains were streaked on proper LB agar plate and incubated at 37°C
overnight. A single colony was taken for inoculation in 5ml LB broth in a 15ml tube. After inoculation 
for overnight, the inoculum was diluted into 1000 fold of OD600 1.0 in 500ml LB broth in the 1L conical 
flask. The flask was incubated at 37°C shaking incubator for 24 hours. The cells were centrifuged at 
7000 RPM for 15 minutes then filtered through a 0.22μ filter to remove all the cells and cell debris. The 
vesicles in the filtrate were concentrated using Amicon 100K centrifugal filter on 5,000 RPM(2935Ｘg
RCF) at room temperature(22 to 24°C) using Centrifuge 5430R(Eppendorf, USA) with the proper
amount of time to concentrate the whole inoculum into the final volume of 0.4~0.5 ml. 
Concentrated vesicles were size-fractionated by density gradient centrifugation using the
OptiprepTM medium. Vesicle sample was mixed with OptiprepTM (Sigma) 60% to make 1ml of 40% 
OptiprepTM-vesicle mixture. Each concentration of OptiprepTM solutions (30%, 25%, 15%, 10%) was
prepared diluted in deionized water and slowly pipetted into the tubes containing each sample so that 
the OptiprepTM gradient were visible to stack up from highest concentration to lowest concentration 
from bottom to up in the ultracentrifuge tube. The tube was hooked on SW 41 swinging rotor and rotated 
at 100,000ｘg (24,149 RPM) for 16 hours at 4°C using OptimaTM L-100XP 
Ultracentrifuge(BACKMAN COULTER, USA). Each concentration was carefully collected, 500μl 
from the top. The proper concentration sample was selected by silver staining and diluted > 6 fold in
DPBS and centrifuged in 100 Ti rotor with a 6ml sealing tube for 8 hours at 50,000 RPM(200480Ｘg) 
using OptimaTM L-100XP Ultracentrifuge(BECKMAN COULTER, USA) at 4°C in order to remove 
OptiprepTM. Vesicle pellet was collected in the 1.5ml tube.
2.6 Silver staining of fractionated vesicle by OptiPrepTM density gradient
The proper concentration of the OptiprepTM which contains a higher concentration of vesicles 
with relatively less concentration of impurities has been determined using Silver staining. An aliquot of 
the concentration from 15% to 30% was linearized using Protein dye. 40% have been excluded because 
it is known to contain impurities such as free proteins, flagella, and DNAs. The samples of different 
OptiprepTM concentrations were loaded on 10% Mini-PROTEAN® TGXTM precast protein gel (BIO-
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RAD, USA) then ran for the SDS-PAGE on PowerPacTM HC(BIO-RAD, USA) with 80V. An hour and 
a half later, the gel was cast off and washed with pure water. Silver staining is done by following the 
protocol in the Silver staining kit (ProteoSilverTM, SIGMA-ALDRICH, USA).
2.7 Membrane vesicle Quantification
E.coli BW25113 wild-type and NlpI knock-out was cultured on 5ml of LB in 15ml Falcon 
tube and E.coli BW25113 ∆NlpI pCMV mCherry was cultured on 5ml of LB with 50ug/ml Kanamycin
for overnight at 37°C then seed culture was diluted to OD1 and inoculated on the 500ml of LB in 1L 
flask for 1000 fold (for ∆NlpI pCMV mCherry strain, 50ug/ml of Kanamycin was also used). The 
inoculum was cultured for 24hrs at 37°C. Vesicles were purified following the 2.5 Membrane vesicle 
isolation. The protein concentration of each sample was measured using Qubit system including Qubit 
3 Fluorometer and QubitTM Protein Assay Kit(Invitrogen, USA) with the detection range from 0.25 – 5 
μg. Standard was measured on the day of measurement for calibration. 
2.8 Quantification of DNA inside the membrane vesicle
Four aliquots of one vesicle sample were taken. The first sample is not treated with any 
chemicals and stored in 4°C. The second is treated with 0.126% TritonTM X-100 (SIGMA Life Science, 
USA) for 30 minutes or more. The third is treated with 2.5unit/ml of DNase with 0.5mM MgCl for 
30minutes in 37°C. The fourth is treated with DNase in the same way and then DNase has been 
deactivated by heat treatment on 56°C for 15 minutes. DNA inside the vesicle was measured using 
Qubit system including Qubit 3 Fluorometer and QubitTM dsDNA BR Assay Kit with a detection range 
from 2 – 1000ng(Invitrogen, USA). Standard was measured on the day of measurement for calibration.
2.9 Imaging the Vesicle Invasion
10,000 cell/well of Hela cell were plated on 8 well chamber and incubated at 37°C with 5% 
CO2 for 36 hours. Vesicles purified from E.coli BW25113 ∆NlpI and E.coli BW25113 ∆NlpI INV/LLO 
was diluted in serum-free-cell culture media, MEM with Cy5 dye(Thermo Fisher Scientific, USA)
which is red fluorescence dye. Cells were treated with CellTracker Violet BMQC (Thermo Fisher 
Scientific, USA) which green fluorescence dye. Vesicles with dye mixture were washed with DPBS 2 
to 3 times and treated to the cell. The vesicle treated cells were incubated at 37°C with 5% CO2 for 2 
hours. Then cells were fixed with 5% paraformaldehyde. For the confocal settings, Cy5 set as Alexa 
Fluor 647, since it shares the excitation range. (633nm or 647nm) 
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2.10 Transfection of mammalian cells with mCherry containing vesicle
10,000 cell/well of Hela and HEK293 cells were plated on 96 well cell culture plate (SPL LIFE 
SCIENCES, Republic of Korea) and incubated at 37°C with 5% CO2 for 36 hours. Mammalian cells 
were treated with the vesicles from E.coli BW25113 ∆nlpI INV/LLO pCMV mCherry plasmid with 
mammalian promotor. After 24 hours of treatment, vesicles were removed and the media was changed 
to serum containing media. After another 48 hours of incubation at 37°C with 5% CO2, mCherry
expressions were observed under confocal microscope.
2.11 MTT assay
50,000 cell/well of Hela cell were plated on four 12 well cell culture plate(SPL LIFE 
SCIENCES, Republic of Korea) and incubated at 37°C with 5% CO2 for 36 hours. One plate is used for 
the whole bacteria treatment and others are used for the vesicle treatment. E.coli BW25113 wild-type, 
E.coli BW25113 ∆nlpI, E.coli BW25113 ∆nlpI INV/LLO, and E.coli BW25113 ∆nlpI INV/LLO pCMV 
mCherry were cultured in 5ml LB in 15ml tube overnight and diluted into 5ml LB by 100 fold 2 to 3 
hours prior to the treatment. These inoculums were used as a whole bacterium and 1μl and 0.1μl of it is 
diluted in 1ml of MEM-serum free media. 100μl of the bacteria mix was added to each well. Bacterial 
cells were removed after 6 hours of incubation. MEM+Gentamycin(50μg/ml) media were added to 
eliminate remaining bacteria. Vesicles were purified from E. coli BW25113 ∆nlpI, E. coli BW25113 
∆nlpI INV/LLO, and E. coli BW25113 ∆nlpI INV/LLO pCMV mCherry according to the protocol 
above. Vesicle samples were diluted in MEM-serum free media to make a final concentration of
25μg/ml, 50μg/ml, and 100μg/ml and treated 500μl for each well and incubated at 37°C with 5% CO2 
for 12 hours. Media was removed and changed with 500μl of 10% dilution of MTT(5mg/ml) in 
MEM(total MMT concentration: 500μg/ml). The cells with MTT were incubated in dark at 37°C with 
5% CO2 for 2 to 4 hours until the MTT changes color. Upon removal of the 10% MTT+MEM solution, 
DMSO was added to the samples including empty well without MTT treatment and incubated at 37°C 
for 30 minutes. The 550nm absorbance was measured with Infinite M200 microplate reader(Tecan, 
Switzerland) using Magellan 6
2.12 Live/Dead Staining
10,000 cell/well of Hela cell were plated on three 96 well cell culture plate(SPL LIFE 
SCIENCES, Republic of Korea) and incubated at 37°C with 5% CO2 for 36 hours. One plate is used for 
the whole bacteria treatment and others are used for the vesicle treatment. E.coli BW25113 wild-type, 
E.coli BW25113 ∆nlpI, E.coli BW25113 ∆nlpI INV/LLO, and E.coli BW25113 ∆nlpI INV/LLO pCMV 
mCherry were cultured in 5ml LB in 15ml tube overnight and diluted into 5ml LB by 100 fold 2 to 3 
14
hours prior to the treatment. These inoculums were used as a whole bacterium and 1μl and 0.1μl of it is 
diluted in 1ml of MEM-serum free media. 100μl of the bacteria mix was added to each well. Bacterial 
cells were removed after 6 hours of incubation. MEM+Gentamycin(50μg/ml) media were added to 
eliminate remaining bacteria. Vesicles were purified from E. coli BW25113 ∆nlpI, E. coli BW25113 
∆nlpI INV/LLO, and E. coli BW25113 ∆nlpI INV/LLO pCMV mCherry according to the protocol 
above. Vesicle samples were diluted in MEM-serum free media to make a final concentration of 
10μg/ml, 25μg/ml, 50μg/ml, and 100μg/ml and treated 100μl for each well and incubated at 37°C with 
5% CO2 for 24 hours. Media from cells were removed and cells are treated with 100μl of Calcein AM 
with propidium iodide solution and incubated for 10 minutes. After incubation, cells were washed with 
DPBS twice and treated with 5% paraformaldehyde. Dyed cells were views under a confocal
microscope.
2.13 Enzyme-linked immunosorbent assay(ELISA)
50,000 Hela cells were plated on 12 well plate and incubated at 37°C with 5% CO2 for 36 
hours. One plate is used for the whole bacteria treatment and others are used for the vesicle treatment. 
These inoculums were used as a whole bacterium and diluted into proper concentration in which cell 
toxicity is low in MEM-serum free media. Bacterial cells were removed after 6 hours of incubation. 
MEM+Gentamycin(50μg/ml) media were added to eliminate remaining bacteria. Vesicles were purified 
from E. coli BW25113 ∆nlpI, E. coli BW25113 ∆nlpI INV/LLO, and E. coli BW25113 ∆nlpI INV/LLO 
pCMV mCherry according to the protocol above. Vesicle samples were diluted in MEM-serum free
media to make proper final concentration with low cell toxicity. Media from each well is collected into
a 1.5ml tube and centrifuged for 5 minutes at max speed (13,200 RPM, 16,100Ｘg) using centrifuge 
5415R(Eppendorf, USA). Supernatants were collected and stored in -20°C. Enzyme-linked 
immunosorbent assay was done according to the protocol in Quantikine® ELISA Human IL-8/CXCL8 
Immunoassay kit (R&D Systems, USA).
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Chapter 3 Results
3.1 NlpI knock-out E. coli overproduces Membrane Vesicles
E. coli BW25113 wild-type, E. coli BW25113 ∆nlpI, and E. coli BW25113 ∆nlpI INV/LLO 
strains was cultured to compare the vesicle production. Produced vesicles were centrifuged and filtered 
to remove the bacterial cell and concentrated, then purified using different density gradient of 
OptiprepTM to size-fractionate the vesicles from all the impurity. (Figure 3.1.1) The proper fraction was 
selected according to the Silver staining results (Figure 3.1.2). The vesicle production was determined 
by measuring the protein concentration of the concentrated and purified vesicles. The final vesicle 
concentration was divided by total volume and CFU data of each sample to normalize the volume 
difference and total cell difference. The normalized vesicle concentration of E. coli BW25113 ∆nlpI
and E. coli BW25113 ∆nlpI INV/LLO was divided by that of E. coli BW25113 wild-type to show the 
relative increment in membrane vesicle production. The fold difference between wild-type(w.t.) and 
NlpI knockout(∆nlpI) was 60.9(±23.3)(n=3). The fold difference between wild type and ∆nlpI
INV/LLO strain vesicle was 75.6(±27.5)(p<0.05)(n=3). The result shows that NlpI knock-out with 
INV/LLO strain produces the significantly higher amount of vesicle compared to the wild type.(Figure 
3.1.3)
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Figure 3.1.1 Concentration gradient layer of OptiprepTM
Each bacterial strains were inoculated in 5ml LB in a 15ml tube with proper antibiotics for overnight. 
Seed cultures were inoculated into 500ml of LB in 1L flask with 1/1000-fold dilution and cultured for 
24hrs. Bacterial cells were removed by centrifugation and filtration with a 0.22μ filter. Membrane 
vesicles were concentrated using 100KDa centrifugal filter. Concentrated membrane vesicles were 
placed in tube then different concentration of OptiprepTM was stacked upon sample gently so that 
gradient layers weren’t mixed
Figure 3.1.2 Silver Staining of size-fractionated Vesicle using Optiprep Density Gradient
0.5ml of each fragment of Optiprep concentration were taken from top-down then ran on the SDS-
PAGE for Silver staining to show which fragment of concentration has impurity or vesicle.
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Figure 3.1.3 Relative Membrane Vesicle production
E. coli BW25113 w.t. was cultured on 5ml of LB in 15ml Falcon tube and E.coli BW25113 ∆nlpI pCMV 
mCherry was cultured on 5ml of LB with 50ug/ml Kanamycin for overnight at 30°C then seed culture 
was diluted to OD600 1 and inoculated on the 500ml of LB in 1L flask with 1000 fold dilution. (for ∆nlpI
pCMV mCherry strain, 50ug/ml of Kanamycin was also used) The inoculum was cultured for 24 hours 
at 30°C. The outer membrane vesicle from each sample was extracted using the centrifugal method. 
The cell pellets were removed by centrifuging at 7,000RPM(2739Ｘg) for 15 minutes using Supra 
22K(HANIL, Republic of Korea) The supernatant was filtered through either Millex-GP 0.22μ syringe 
filter(Merck, USA) or Steritop-GP 0.22μ filter(Merck, USA) then filtered through 100kDa Amicon 
Ultra-15 Centrifugal Filter Units(Merck, USA) to be concentrated. The concentrated samples were 
purified through OptiPrepTM gradient method. 1.2 μl of w.t. vesicles and 2.4 μl of ∆nlpI pCMV mCherry
vesicles were mixed with OptiPrepTM (Sigma, USA) to 40%(v/v) in clear ultracentrifuge tube 
(BECKMAN COULTER). 30%, 25%, 20%, 15% of OptiPrepTM solution diluted in deionized water 
were slowly pipetted into the tubes containing each sample so that the OptiPrepTM gradient were visible. 
The samples were centrifuged using SW41 rotor at 100000g(RCF), 4°C, for 16 hours. The centrifuged 
samples were collected from the top, 500μl each. The protein concentration of each sample was
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3.2 E. coli Membrane can invade into and transfect the mammalian cell
By comparing the confocal image of ∆nlpI vesicle dyed with Cy5 with the negative control, 
the vesicles produced by E. coli BW25113 NlpI knock-out strain cannot invade into the Hela cell. The 
confocal image of vesicle treated cell shows that the vesicle with the invasin and the listeriolysin are 
able to invade into the human cell. (Figure 3.2.1) The 3D image was acquired using Z-stack. One 
intersection of the serial Z-stack image shows that the vesicles are inside of the mammalian cell rather 
than simply attaching to the surface. (Figure 3.2.2) The result indicates that the vesicle produced by 
INV/LLO plasmid containing E. coli BW25113 strain is essential for invasion of the vesicle into the 
target cell. Therefore E. coli BW25113 pCMV mCherry INV/LLO strain was selected to produce 
vesicles for the transfection into the human cell line in vitro. 
Transfection using bacterial membrane vesicle containing pCMV mCherry plasmid was done 
as described on 2.10 Transfection of the mammalian cell with mCherry containing vesicle. High 
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Figure 3.2.1 
Confocal Image 
of MV invasion 
into Mammalian 
cell
Cy5 is a red-
fluorescent dye 
with excitation and 
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vio is a green-
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shows cell image. 
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Figure 3.2.2 Dissection of Confocal Z-stack image
Showing that the vesicles are internalized in the cell. Magenta color is the vesicle/Cy5
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Figure 3.2.4 Confocal image of the mammalian cell with the mCherry expressions
Mammalian cells were treated with the vesicles of E. coli BW25113 INV/LLO ∆nlpI pCMV mCherry 
plasmid with mammalian promotor. After 24 hours, the mCherry expressions were observed under 
confocal microscope.
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3.3 E. coli Membrane Vesicle are less cytotoxic towards mammalian cell lines 
Whole bacteria cells of E. coli BW25113 wild-type and E. coli BW25113 ∆nlpI was diluted 
1μl in 1ml serum-free MEM. The colony forming units(CFU) of each bacterial samples were counted 
to determine the multiplicity of infection (MOI) 12.4(±1.40) for E. coli BW25113 wild-type and MOI 
19.4(±7.10) for E. coli BW25113 ∆nlpI. Before measurement, the plates were shaken for 10 seconds 
with 2.5 magnitudes, orbitally to ensure even distribution of MTT dye. The MTT absorbance of 
550nm from each well was taken from 3Ｘ3 spot. MTT absorbance of 550nm of each sample was
divided with that of the negative control which is the Hela cell without any treatment to calculate 
relative viability(%) of each sample. The MTT assay result shows that vesicle produced are relatively 
non-cytotoxic on the mammalian cell with the concentration lower than 25μg/ml compared to the 
whole bacteria treatment. (Figure 3.3.1 and Figure 3.3.2) 100μg/ml of E. coli BW25113 ∆nlpI vesicle 
showed 76.3(±13.5)% of relative viability which is compatible to the relative viability of whole 
bacteria treated samples such as relative viability of 76.8(±18.6)% of E. coli BW25113 wild-type
bacteria treated sample or 76.3(±14.0)% of E. coli BW25113 ∆nlpI whole bacteria treated one.(Figure 
3.3.2) The t-test revealed that it is significantly different from the negative control(*p<0.05). E. coli 
BW25113 ∆nlpI INV/LLO vesicle with 100μg/ml concentration showed 83.2(±4.74)% of relative 
viability with a significant difference compared to the negative control(**p<0.01). E. coli BW25113 
∆nlpI INV/LLO vesicle with 50μg/ml is also showed significant difference with the control(*p<0.05).
(Figure 3.3.1)
The confocal image reveals the morphology of the vesicle treated cell is in healthy shape 
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*
***
Figure 3.3.1 MTT assay result of Vesicle treated samples
Relative viability of each vesicle treated Hela cell samples compared with negative control which is 























MTT of Hela treated with whole bacteria
*
*
Figure 3.3.2 MTT assay result of the whole cell 
treated
Each Hela MTT sample is compared with the negative 
control group and divided by negative control value to 
show the relative viability. *p<0.05 
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Figure 3.3.3 Morphology of the vesicle treated cell
Red arrow points at the red-dyed dead cell debris. 
Green fluorescence represents the viable Hela cell.
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Chapter 4 Conclusion
The current advance in the biology and biotechnology field aims at individualized treatment, 
especially genetic manipulation for gene therapy. However, a proper transfecting agent that is 
applicable both in vivo and in-vitro with easy application, massive production, and low risk is scarce[5, 
14, 15, 19, 21, 23]. Therefore, through studies, I suggest bacterial membrane vesicle as a possible candidate 
for the delivery vector. 
By transforming E. coli type strains with the desired plasmid which is associated with cell 
invasion, invasion into the human cell was significantly increased so that was visualized in the
confocal image. Using the nlpI knock-out strain to produce a large quantity of vesicle compare to 
wild-type not only secures the amount of vesicle required for the study but also suggest that the 
bacterial membrane vesicle can be produced in large quantity which is essential when it comes to 
commercialization.
The invasion of bacterial MVs into the mammalian cells were demonstrated and the transfer 
of the plasmid into the mammalian cell and its expression was verified.
The cytotoxicity assay such as MTT assay was done to determine the maximum
concentration of the bacterial membrane vesicle that does not exert the cell death nor morphology 
change. Comparing the viability of the mammalian cell treated with different concentrations of the 
bacterial membrane vesicle with those of the Lipofectamine 2000 which is a commercialized and 
widely used chemical transfecting agent revealed that the bacterial membrane vesicle is far less 
cytotoxic than the chemical transfecting agent. The non-cytotoxic concentration of the bacterial 
membrane vesicle was 25μg/ml whereas the Lipofectamine 2000 treatment showed 25% cell viability 
with 20μg/ml.[40]
Through my study, I have demonstrated that the bacterial vesicle can be mass produced, 
invades into the target cell and delivers the DNA without killing or changing the target cell, therefore 
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